TP53 Mutations Promote Immunogenic Activity in Breast Cancer.

Zhixian LiuZehang JiangYingsheng GaoLirui WangCai ChenXiao-Sheng Wang

Published in: Journal of oncology (2019)

TP53 mutations may promote immunogenic activity in BC, suggesting that the TP53 mutation status could be a useful biomarker for stratifying BC patients responsive to immunotherapy.

Keyphrases

end stage renal disease
ejection fraction
newly diagnosed
chronic kidney disease
peritoneal dialysis
prognostic factors
young adults